2 Information about lutetium-177 vipivotide tetraxetan

Marketing authorisation indication


Lutetium‑177 vipivotide tetraxetan (Pluvicto, Advanced Accelerator Applications) is indicated for 'the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes'.

Dosage in the marketing authorisation



The list price of lutetium‑177 vipivotide tetraxetan is £20,000 per 7,400 MBq single dose vial per treatment cycle (excluding VAT; company submission). The company has a commercial arrangement, which would have applied if the technology had been recommended.

  • National Institute for Health and Care Excellence (NICE)